Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 19, 2025
Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress
GlobeNewswire
·
May 19, 2025
Results from MUSIC-HFpEF Phase 1/2a clinical trial show favorable safety profile and early clinical benefits with SRD-002 gene therapy BOSTON, May 19, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on …
Alignment Health Plan Recognized as One of Two Medicare Advantage Prescription Drug Plans in the U.S. for Excellence in Pharmacy Quality
GlobeNewswire
·
May 19, 2025
ORANGE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) has been recognized for excellence in quality for its Medicare Advantage prescription drug (MAPD) plan by the Pharmacy Quality Alliance (PQA). The PQA has measured …
Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference
GlobeNewswire
·
May 19, 2025
WARRINGTON, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies …
Eascra Biotech Awarded $100,000 MassVentures START Grant
GlobeNewswire
·
May 19, 2025
BOSTON, May 19, 2025 (GLOBE NEWSWIRE) -- Eascra Biotech, a nanomedicine startup, has been awarded a $100,000 Stage I SBIR Targeted Technologies (START) grant funded by the Commonwealth and managed by MassVentures. The funding is to support their work on …
Respira Therapeutics Announces Late-breaking Presentation of RT234 Phase 2b PAH Clinical Trial Results at the American Thoracic Society (ATS) 2025 International Conference
GlobeNewswire
·
May 19, 2025
PALO ALTO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Respira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing RT234 (vardenafil inhalation powder) as the first therapy that pulmonary arterial hypertension (PAH) patients …
Rani Therapeutics Announces Research Agreement with Chugai
GlobeNewswire
·
May 19, 2025
- Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “ …
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
GlobeNewswire
·
May 19, 2025
SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been dosed with CX-801 in combination …
Reflect Scientific Strengthens Position in Booming AI Data Center Cooling Market with Patented Cryogenic Innovations
GlobeNewswire
·
May 19, 2025
OREM, Utah, May 19, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a pioneer in cryogenic cooling technologies, today highlighted how its patented solutions are uniquely positioned to address the surging global demand for advanced data …
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
GlobeNewswire
·
May 19, 2025
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence shows target market for efzofitimod …
Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders
GlobeNewswire
·
May 19, 2025
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that …
STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments, Unlocking Access for Millions with Inflammatory and Auto-Immune Skin Diseases
GlobeNewswire
·
May 19, 2025
HORSHAM, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to advancing dermatologic care through innovation, announces that the American Medical Association …
Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value
GlobeNewswire
·
May 19, 2025
Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Keros …
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
GlobeNewswire
·
May 19, 2025
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 19, 2025 (GLOBE …
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
GlobeNewswire
·
May 19, 2025
Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively enrolling patients in 20 countries, with all sites expected to …
Atsena Therapeutics Announces Positive Clinical Data from Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy to Treat X-linked Retinoschisis (XLRS)
GlobeNewswire
·
May 19, 2025
First XLRS study to demonstrate efficacy and positive safety data in a Phase I/II trial Majority of patients demonstrated successful efficacy readouts across structural measurements (foveal schisis closure) and had meaningful improvement on visual function …
Reunion Neuroscience Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
GlobeNewswire
·
May 19, 2025
-- Enrollment Completed on Schedule; Topline Results Expected Q3 2025 -- -- Company to Present Poster Reviewing RE104 Phase 1 Results at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting on May 28, 2025 -- MORRISTOWN, N.J., May 19, …
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
GlobeNewswire
·
May 19, 2025
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the …
Gradient Denervation Technologies Announces FDA Breakthrough Designation for Pulmonary Artery Denervation System
GlobeNewswire
·
May 19, 2025
PARIS, May 19, 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies announced today the company’s pulmonary denervation system has received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This program creates an …
Gradient Denervation Technologies annonce que son système de dénervation de l’artère pulmonaire a obtenu la désignation de dispositif innovant par la FDA
GlobeNewswire
·
May 19, 2025
PARIS, 19 mai 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies a annoncé aujourd’hui que son système de dénervation pulmonaire a reçu la désignation de dispositif innovant de la part de la Food and Drug Administration (FDA), l’Agence américaine …
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
GlobeNewswire
·
May 19, 2025
Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe’s customer data; stands ready to work with independent, court-appointed Customer Privacy Ombudsman Planned purchase …